Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Net Income Loss of -$6.08 million for the year ending 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -69.5% in Net Income Loss from 2024 to 2025.
- This data is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 20 years of available data (2006 to 2025), LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Net Income Loss has declined by 981.4%.
- Historical annual values: Fiscal year 2025: -$6.08 million | Fiscal year 2024: -$3.59 million | Fiscal year 2023: -$5.09 million | Fiscal year 2022: -$6.31 million | Fiscal year 2021: -$6.73 million | Fiscal year 2020: -$3.26 million | Fiscal year 2019: -$2.44 million | Fiscal year 2018: -$2.13 million | Fiscal year 2017: -$1.81 million | Fiscal year 2016: -$2.13 million | Fiscal year 2015: -$2.85 million | Fiscal year 2014: -$2.77 million | Fiscal year 2013: -$1.37 million | Fiscal year 2012: -$3.58 million | Fiscal year 2011: -$2.07 million | Fiscal year 2010: -$880.3 thousand | Fiscal year 2009: -$1.55 million | Fiscal year 2008: -$1.27 million | Fiscal year 2007: -$1.65 million | Fiscal year 2006: -$562.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: